Ad
related to: kite pharma stock
Search results
Results From The WOW.Com Content Network
Kite Pharma, Inc. is an American biotechnology company that develops ... of its common stock. [45] In June 2014, Kite Pharma sold 8,625,000 shares of its common stock ...
The stock is up nearly 6% Thursday, trading at more than $96 per share, compared to a market close price of $91.69 per share. ... That includes the $12 billion acquisition of Kite Pharma, which ...
In April 2014, Kite Pharma completed a $50 million mezzanine private financing of convertible notes, [9] and in May, the company filed a registration with the SEC for an IPO of its common stock, with a proposed maximum offering price of $115 million. The company listed on the NASDAQ Global Market under the symbol "KITE."
Valeant Pharmaceuticals: Allergan, Inc: 53.3 71 Valeant raised its unsolicited offer for Allergan a second time, to $53.3 billion, increasing the cash portion of the bid in an effort to win the backing of the company, with the cash-and-stock portion of the bid valuing each Allergan share at $179.25. [26] 16 2014 Valeant Pharmaceuticals ...
The Motley Fool Stock Advisor analyst team just identified what they believe are the 10 best stocks for investors to buy now… and Vertex Pharmaceuticals wasn’t one of them. The 10 stocks that ...
For premium support please call: 800-290-4726 more ways to reach us
In August 2017, the company announced it would acquire Kite Pharma for $11.9 billion, [55] equating to $180 cash per share, a 29% premium over the closing price of the shares. The deal was Gilead's entry into the cell therapy market and added a chimeric antigen receptor T cell ( CAR-T ) therapy candidate to the company's portfolio. [ 56 ]
The following video is part of our "Motley Fool Conversations" series, in which health-care editor/analyst David Williamson discusses topics across the investing world. In this video, David picks ...